{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:38:50Z","timestamp":1769884730606,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Placenta"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.placenta.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:40:26Z","timestamp":1767976826000},"page":"245-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Maternal soluble suppression of Tumorigenicity-2 as a biomarker for fetal growth restriction: Clinical correlations and diagnostic performance"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3758-0136","authenticated-orcid":false,"given":"Sadun","family":"Sucu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadullah","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alperen","family":"Aksan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belgin","family":"Savran \u00dc\u00e7ok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turhan","family":"\u00c7a\u011flar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.placenta.2026.01.004_bib1","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/AOG.0000000000003070","article-title":"ACOG practice bulletin no. 204: fetal growth restriction","volume":"133","year":"2019","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.placenta.2026.01.004_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/OGX.0000000000001203","article-title":"Fetal growth restriction: a comprehensive review of major guidelines","volume":"78","author":"Giouleka","year":"2023","journal-title":"Obstet. Gynecol. Surv."},{"issue":"3","key":"10.1016\/j.placenta.2026.01.004_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/FM9.0000000000000156","article-title":"The update of fetal growth restriction associated with biomarkers","volume":"4","author":"Sun","year":"2022","journal-title":"Matern. Fetal. Med."},{"issue":"1","key":"10.1016\/j.placenta.2026.01.004_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01389-x","article-title":"Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study","volume":"11","author":"Rezar","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.placenta.2026.01.004_bib5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00296-020-04554-z","article-title":"Interleukin-33\/suppression of tumorigenicity 2 (IL-33\/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study","volume":"40","author":"Opinc","year":"2020","journal-title":"Rheumatol. Int."},{"issue":"8","key":"10.1016\/j.placenta.2026.01.004_bib6","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.21037\/tcr-23-792","article-title":"Prognostic role of serum soluble ST2 of advanced breast cancer patients: a retrospective cohort study","volume":"12","author":"Chen","year":"2023","journal-title":"Transl. Cancer Res."},{"issue":"11","key":"10.1016\/j.placenta.2026.01.004_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293844","article-title":"Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes","volume":"18","author":"Moon","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.placenta.2026.01.004_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.placenta.2024.12.012","article-title":"Profilin-1 levels in preeclampsia: associations with disease and adverse neonatal outcomes","volume":"159","author":"\u00d6zkan","year":"2025","journal-title":"Placenta"},{"issue":"2","key":"10.1016\/j.placenta.2026.01.004_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020915832","article-title":"Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect","volume":"10","author":"Pratama","year":"2020","journal-title":"Pulm. Circ."},{"issue":"1","key":"10.1016\/j.placenta.2026.01.004_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/0886022X.2020.1767648","article-title":"Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study","volume":"42","author":"Wang","year":"2020","journal-title":"Ren. Fail."},{"issue":"4","key":"10.1016\/j.placenta.2026.01.004_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/00365513.2021.1904518","article-title":"Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study","volume":"81","author":"Filali","year":"2021","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"1","key":"10.1016\/j.placenta.2026.01.004_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/14767058.2022.2153034","article-title":"Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia","volume":"36","author":"Kanninen","year":"2023","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"9","key":"10.1016\/j.placenta.2026.01.004_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024463","article-title":"ST2 and IL-33 in pregnancy and pre-eclampsia","volume":"6","author":"Granne","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.placenta.2026.01.004_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/14767058.2017.1286319","article-title":"Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study","volume":"31","author":"Romero","year":"2018","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"14","key":"10.1016\/j.placenta.2026.01.004_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3109\/14767058.2013.784256","article-title":"Maternal plasma concentrations of sST2 and angiogenic\/anti-angiogenic factors in preeclampsia","volume":"26","author":"Stampalija","year":"2013","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"3","key":"10.1016\/j.placenta.2026.01.004_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: a Delphi procedure","volume":"48","author":"Gordijn","year":"2016","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.placenta.2026.01.004_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/uog.22134","article-title":"ISUOG practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction","volume":"56","author":"Lees","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.placenta.2026.01.004_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/uog.20854","article-title":"Validation of Delphi procedure consensus criteria for defining fetal growth restriction","volume":"56","author":"Molina","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.placenta.2026.01.004_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.placenta.2018.01.003","article-title":"Soluble ST2, a preeclampsia-related cytokine receptor, is transported bi-directionally across the placenta","volume":"63","author":"Kong","year":"2018","journal-title":"Placenta"},{"issue":"2","key":"10.1016\/j.placenta.2026.01.004_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G\u2217Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.placenta.2026.01.004_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 axis in immune cells during inflammatory diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front. Immunol."},{"issue":"2\u20133","key":"10.1016\/j.placenta.2026.01.004_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cytogfr.2004.02.004","article-title":"T1\/ST2--an IL-1 receptor-like modulator of immune responses","volume":"15","author":"Trajkovic","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.placenta.2026.01.004_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14767058.2019.1609934","article-title":"Elevated soluble-St2 concentrations in preeclampsia correlate with echocardiographic parameters of diastolic dysfunction and return to normal values one year after delivery","volume":"34","author":"Mugerli","year":"2021","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"2","key":"10.1016\/j.placenta.2026.01.004_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.preghy.2013.02.002","article-title":"Measurement of sST2 is comparable to PlGF in the diagnosis of early-onset pre-eclampsia","volume":"3","author":"Southcombe","year":"2013","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.placenta.2026.01.004_bib25","article-title":"Differences in maternal soluble ST2 levels in the third trimester of normal pregnancy versus preeclampsia","volume":"13","author":"Sasmaya","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol. X"},{"key":"10.1016\/j.placenta.2026.01.004_bib26","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.938218","article-title":"Suppression of tumorigenicity 2 pro-inflammatory biomarker linking diabetes mellitus and periodontitis: a pilot study","volume":"28","author":"Navya","year":"2022","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"10.1016\/j.placenta.2026.01.004_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/14767058.2023.2183470","article-title":"A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2","volume":"36","author":"Chatterton","year":"2023","journal-title":"J. Matern. Fetal Neonatal Med."}],"container-title":["Placenta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400426000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400426000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:23:33Z","timestamp":1769837013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143400426000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S0143400426000135"],"URL":"https:\/\/doi.org\/10.1016\/j.placenta.2026.01.004","relation":{},"ISSN":["0143-4004"],"issn-type":[{"value":"0143-4004","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maternal soluble suppression of Tumorigenicity-2 as a biomarker for fetal growth restriction: Clinical correlations and diagnostic performance","name":"articletitle","label":"Article Title"},{"value":"Placenta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.placenta.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}